OmniAb Results Presentation Deck

Active Programs GROWTH AND PROGRESSION CONTINUES Number of Active Programs 350 300 250 200 150 100 50 2016 2017 2018 2019 2020 2021 2022 6/30/2023 ● ● Number of Active Programs reached 305 (net of discovery- stage attrition) Active Programs: ~25% CAGR 2016 through 2022 Regulatory (License Application/BLA), clinical and preclinical progression of programs continues, and new discovery-stage programs added Phase 1: 22 Preclinical: 15 305 Active Programs as of 06/30/2023 Phase 2: 2 Phase 3: 1 Represents programs for which research work has commenced or an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. BLA: 1 Approved: 3 Discovery: 261 8 OmniAb

View entire presentation